Staff / TruthdigMay 25, 2016
Wall Street’s drive for profits is diminishing the benefits to society of new life-enhancing medications for which companies can charge patients hundreds of thousands of dollars per year. Dig deeper ( 2 Min. Read )
Staff / TruthdigFeb 5, 2016
Embattled Turing Pharmaceuticals CEO Martin Shkreli apparently did not show up for his hearing Thursday before the House Oversight Committee with a mind to shift public opinion in his favor or convince attendant legislators that he held anything resembling respect for the proceedings. Dig deeper ( 2 Min. Read )
Staff / TruthdigDec 18, 2015
The 32-year-old Turing Pharmaceuticals CEO and Wall Street player became a source of schadenfreude on a mass scale Thursday with the news that he had been arrested for securities fraud. Dig deeper ( 3 Min. Read )
Join our newsletterStay up to date with the latest from Truthdig. Join the Truthdig Newsletter for our latest publications.
Alexander Reed Kelly / TruthdigNov 26, 2015
The disreputable pharmaceutical boss has reneged on an agreement to lower the price of a medication he raised from $13.50 to $750 per pill. Dig deeper ( 1 Min. Read )
Staff / TruthdigNov 5, 2015
Republican Jason Chaffetz, chairman of the House Committee on Oversight and Governmental Reform, has been accused of protecting drug companies Valeant and Turing Pharmaceuticals from a congressional investigation into alleged price gouging. Dig deeper ( 2 Min. Read )
Kasia Anderson / TruthdigOct 5, 2015
Another drug company has joined the likes of the recently exposed Turing Pharmaceuticals by jacking up prices of life-sustaining meds on extremely short notice. Remember this name: Valeant Pharmaceuticals International. Dig deeper ( 1 Min. Read )
BLANKSep 27, 2015
The drug company CEO who announced a 5,000 percent increase in the price of a lifesaving drug was forced to back down after Twitter users, the industry and others exploded in outrage. We have three words for these sometimes rude commenters: Good for you. Dig deeper ( 3 Min. Read )
Staff / TruthdigSep 23, 2015
In case you hadn't heard, last month, Turing Pharmaceuticals CEO and former hedge fund manager Martin Shkreli got hold of the rights to parasite-zapping drug Daraprim, and then he had the bright idea to raise the price from $13.50 to $750 per pill. Now he has a big public relations problem and a self-created health care crisis on his hands. Dig deeper ( 1 Min. Read )
Join our newsletterStay up to date with the latest from Truthdig. Join the Truthdig Newsletter for our latest publications.
Now you can personalize your Truthdig experience. To bookmark your favorite articles and follow your favorite authors, please login or create a user profile.
Now you can personalize your Truthdig experience. To bookmark your favorite articles and follow your favorite authors, upgrade to supporter.